Patents by Inventor Matthew Burger
Matthew Burger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779649Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: December 18, 2019Date of Patent: October 10, 2023Assignee: Novartis AGInventors: Matthew Burger, Joseph Anthony D'Alessio, Tony Fleming, Vivek Rauniyar, Eusebio Manchado Robles, Christian Kunz, Markus Waldhuber
-
Publication number: 20220305134Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.Type: ApplicationFiled: June 6, 2022Publication date: September 29, 2022Inventors: Anthony Edward BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO, Ben WEN
-
Patent number: 11357864Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.Type: GrantFiled: December 19, 2017Date of Patent: June 14, 2022Assignee: Novartis AGInventors: Ben Wen, Anthony E. Boitano, Matthew Burger, Susan E. Cellitti, Michael P. Cooke, Catrin Finner, Bernhard Hubert Geierstanger, Yunho Jin, Si Tuen Lee-Hoeflich, HongNgoc Thi Pham, Siew Ho Schleyer, Kathrin Tissot, Tetsuo Uno
-
Publication number: 20200197528Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Inventors: Matthew BURGER, Joseph Anthony D'Alessio, Tony FLEMING, Vivek RAUNIYAR, Eusebio Manchado ROBLES
-
Publication number: 20190321483Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.Type: ApplicationFiled: December 19, 2017Publication date: October 24, 2019Inventors: Ben WEN, Anthony E. BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO
-
Patent number: 9694016Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 13, 2014Date of Patent: July 4, 2017Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele Nishiguchi, Yue Pan, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Sharadha Subramanian, Benjamin Taft, Huw Tanner, Lifeng Wan, Naeem Yusuff
-
Publication number: 20160038504Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: NOVARTIS AGInventors: Robert AVERSA, Paul A. BARSANTI, Matthew BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele NISHIGUCHI, Yue PAN, Valery POLYAKOV, Savithri RAMURTHY, Alice RICO, Lina SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin TAFT, Huw TANNER, Lifeng WAN, Naeem YUSUFF
-
Patent number: 9242969Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 11, 2014Date of Patent: January 26, 2016Assignee: Novartis AGInventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
-
Publication number: 20150336960Abstract: The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 7, 2013Publication date: November 26, 2015Applicant: NOVARTIS AGInventors: Matthew BURGER, Gisele NISHIGUCHI, Alice RICO, Benjamin TAFT
-
Patent number: 9173883Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: November 3, 2015Assignee: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20150150873Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 12, 2015Publication date: June 4, 2015Inventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20150133473Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: May 14, 2015Applicant: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Patent number: 8987457Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: March 24, 2015Assignee: Novartis AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20140275003Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: NOVARTIS AGInventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
-
Patent number: 8829193Abstract: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.Type: GrantFiled: April 16, 2012Date of Patent: September 9, 2014Assignee: Novartis AGInventors: Matthew Burger, Jiong Lan, Mika Lindvall, Gisele Nishiguchi, Michelle Tetalman
-
Publication number: 20140249135Abstract: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: May 9, 2014Publication date: September 4, 2014Applicant: NOVARTIS AGInventors: Matthew Burger, Mika Lindvall, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Cynthia Shafer, Cornelia Bellamacina, Kay Huh, Gordana Atallah, Christopher McBride, William Antonios-McCrea, JR., Tatiana Zavorotinskaya, Annette Walter, Pablo Dominguez Garcia
-
Patent number: 8822497Abstract: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: March 3, 2008Date of Patent: September 2, 2014Assignee: Novartis AGInventors: Matthew Burger, Mika Lindvall, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Cynthia Shafer, Cornelia Bellamacina, Kay Huh, Gordana Atallah, Christopher McBride, William Antonios-McCrea, Jr., Tatiana Zavorotinskaya, Annette Walter, Pablo Garcia
-
Publication number: 20140228363Abstract: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: April 22, 2014Publication date: August 14, 2014Applicant: NOVARTIS AGInventors: Matthew Burger, Yu Ding, Wooseok Han, Gisele Nishiguchi, Alice Rico, Robert Lowell Simons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Patent number: 8759338Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: August 31, 2009Date of Patent: June 24, 2014Assignee: Novartis AGInventors: Matthew Burger, Jiong Lan
-
Patent number: 8735424Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: August 31, 2009Date of Patent: May 27, 2014Assignee: Novartis AGInventors: Matthew Burger, Mika Lindvall